TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01258868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor cell vaccine
Description: A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
Study: NCT02656368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEBORRHEAMEDIS Face Cream
Description: SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
Study: NCT03680053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duphaston
Description: Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Study: NCT04003272

Intervention type: DEVICE
Intervention: Comprehensive Reverse Versa-Dial Titanium Glenosphere
Description: Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
Study: NCT03597711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVcannulation
Description: Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVcannulation
Description: Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVcannulation
Description: Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
Study: NCT02736214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan (RLP)
Description: A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
Study: NCT02229604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA
Description: For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRT, DHEA and herb
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRT, DHEA and herb
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
Study: NCT01023477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Standard Dose (500mg/week)
Description: Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Low Dose (250mg/week)
Description: Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
Study: NCT00582816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinimacs Cell Separation System
Description: Depletion of T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conditioning chemotherapy
Description: Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLI
Description: NK Cell selected DLI
Study: NCT02129777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT03232125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
Study: NCT03485495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divaza
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT01677312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Biopsy
Description: A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Biopsy
Description: A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Histological Samples
Description: The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Histological Samples
Description: The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
Study: NCT01944839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham intravitreal injection
Description: Pressure on the eye with a syringe with no needle
Study: NCT03332511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300mg twice-daily
Study: NCT03222492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
Study: NCT02242240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol twice daily
Study: NCT01645761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endonase
Description: PPI- based triple therapy with endonase
Study: NCT04232449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREDNISON Galepharm Tabl. 20 mg
Description: 5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: 5 daily- doses of placebo (2 tablets)
Study: NCT05191628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Visio-AMTRIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
Study: NCT02848547

Intervention type: BEHAVIORAL
Intervention: Text Messaging via Short Message Service
Study: NCT03251547

Intervention type: DRUG
Intervention: NovoSeven
Description: To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
Study: NCT02986373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous injection.
Study: NCT01615510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol immediate release
Description: 100 mg, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol immediate release
Description: 100 mg, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single administration
Study: NCT02603575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: 70mg ivdrip the first day, then 50mg ivdrip qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin
Description: 70mg ivdrip the first day, then 50mg ivdrip qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
Study: NCT00974454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 2
Description: Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT02603575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfanilamides
Description: 1.92g q8h
Study: NCT02533973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xamiol® gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivonex® scalp solution
Study: NCT02485522

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT03187522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TREO Stent-Graft System
Description: The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
Study: NCT01471886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Every 8 hours for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Every 8 hours for 4 days.
Study: NCT01072890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus, Pazopanib
Description: Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
Study: NCT00974454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT03354377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts/Mailings
Description: Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
Study: NCT02603575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfanilamides
Description: 1.92g q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfanilamides
Description: 1.92g q8h
Study: NCT03222492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for blinding (masking), 0.95% normal saline.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for blinding (masking), 0.95% normal saline.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for blinding (masking), 0.95% normal saline.
Study: NCT02128360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole, Gonadotropins
Study: NCT03354377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts/Mailings
Description: Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
Study: NCT02734147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT02128360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Study: NCT03865576

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive ICP measurement
Description: Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive ICP measurement
Description: Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
Study: NCT02280954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Study: NCT00617643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine without dose escalation
Description: Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine initiation with dose escalation
Description: Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
Study: NCT03080077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricrolin+
Description: The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi-Off
Description: Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
Study: NCT00235001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trandolapril/verapamil
Description: 180/2 mg QD
Study: NCT02656212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epicatechin
Description: 30 mg (+)-epicatechin, taken orally, one pill/day in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, taken orally, one pill/day in the morning
Study: NCT02025556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 High Dose
Description: Subcutaneously Administered High Dose LBR-101 Monthly x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 Low Dose
Description: Subcutaneously Administered Low Dose LBR-101 Monthly x 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study: NCT03778372

Intervention type: DRUG
Intervention: Methadone
Description: see desc above
Study: NCT02603575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfanilamides
Description: 1.92g q8h
Study: NCT04573959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SV-3 Capsule Endoscopy
Description: The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
Study: NCT01172314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA+LEU vs total AA
Description: 15 g as a bolus

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total AA vs EAA+LEU
Description: 15 g as a bolus
Study: NCT03466554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes
Description: 60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
Study: NCT02112045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose melphalan (HDR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose melphalan (HDR)
Study: NCT01477450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-dose oxygen
Description: Pulsed-dose oxygen delivery from an oxygen concentrator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-dose oxygen
Description: Pulsed-dose oxygen delivery from an oxygen concentrator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-dose oxygen
Description: Pulsed-dose oxygen delivery from an oxygen concentrator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylinder oxygen delivery
Description: Oxygen delivery from an oxygen cylinder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylinder oxygen delivery
Description: Oxygen delivery from an oxygen cylinder
Study: NCT02112045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant (ASCT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Study: NCT03681288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful Self-Compassion Intervention
Study: NCT01960907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHROMED monitoring system
Description: Optimization of patient's treatment according to the data collected by the home monitoring devices